Alnylam Pharmaceuticals’ (ALNY) Buy Rating Reaffirmed at Chardan Capital

Chardan Capital reaffirmed their buy rating on shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) in a research report released on Wednesday,Benzinga reports. Chardan Capital currently has a $425.00 price objective on the biopharmaceutical company’s stock.

A number of other research analysts also recently weighed in on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $510.00 target price on shares of Alnylam Pharmaceuticals in a research report on Wednesday. Jefferies Financial Group reissued a “hold” rating and set a $330.00 price target (down from $522.00) on shares of Alnylam Pharmaceuticals in a research report on Monday, March 16th. Barclays assumed coverage on Alnylam Pharmaceuticals in a report on Wednesday, January 28th. They issued an “overweight” rating and a $527.00 price objective for the company. Morgan Stanley lowered their target price on Alnylam Pharmaceuticals from $495.00 to $408.00 and set an “equal weight” rating on the stock in a research report on Friday, January 30th. Finally, Bank of America reiterated a “buy” rating on shares of Alnylam Pharmaceuticals in a report on Thursday, February 12th. One equities research analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating and six have given a Hold rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $468.84.

Alnylam Pharmaceuticals Trading Up 6.7%

NASDAQ ALNY opened at $328.70 on Wednesday. Alnylam Pharmaceuticals has a 52 week low of $205.87 and a 52 week high of $495.55. The company has a debt-to-equity ratio of 1.28, a quick ratio of 2.71 and a current ratio of 2.76. The stock’s 50 day moving average price is $332.13 and its two-hundred day moving average price is $402.21. The stock has a market capitalization of $43.59 billion, a price-to-earnings ratio of 192.22 and a beta of 0.36.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings results on Thursday, February 12th. The biopharmaceutical company reported $1.25 earnings per share for the quarter, missing the consensus estimate of $1.43 by ($0.18). Alnylam Pharmaceuticals had a return on equity of 69.02% and a net margin of 6.43%.The business had revenue of $1.10 billion for the quarter, compared to the consensus estimate of $1.16 billion. During the same period in the prior year, the business earned ($0.65) earnings per share. Alnylam Pharmaceuticals’s revenue was up 84.9% compared to the same quarter last year. As a group, analysts anticipate that Alnylam Pharmaceuticals will post -1.7 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Alnylam Pharmaceuticals news, EVP Jeffrey V. Poulton sold 2,780 shares of the firm’s stock in a transaction on Monday, January 12th. The stock was sold at an average price of $362.87, for a total transaction of $1,008,778.60. Following the completion of the sale, the executive vice president owned 57,465 shares of the company’s stock, valued at $20,852,324.55. This trade represents a 4.61% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Pushkal Garg sold 2,242 shares of the company’s stock in a transaction on Friday, February 13th. The shares were sold at an average price of $310.08, for a total transaction of $695,199.36. Following the completion of the transaction, the executive vice president owned 24,848 shares in the company, valued at approximately $7,704,867.84. This represents a 8.28% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 53,923 shares of company stock valued at $18,072,087 over the last 90 days. 1.50% of the stock is owned by insiders.

Institutional Trading of Alnylam Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the stock. Rockefeller Capital Management L.P. increased its stake in shares of Alnylam Pharmaceuticals by 85.5% during the fourth quarter. Rockefeller Capital Management L.P. now owns 8,124 shares of the biopharmaceutical company’s stock worth $3,231,000 after purchasing an additional 3,744 shares during the period. Hsbc Holdings PLC boosted its stake in Alnylam Pharmaceuticals by 22.6% in the 4th quarter. Hsbc Holdings PLC now owns 89,517 shares of the biopharmaceutical company’s stock valued at $35,675,000 after purchasing an additional 16,503 shares during the period. SHP Wealth Management acquired a new position in Alnylam Pharmaceuticals in the 4th quarter valued at $43,000. Reflection Asset Management bought a new position in Alnylam Pharmaceuticals during the 4th quarter worth $63,000. Finally, Wick Capital Partners LLC bought a new position in Alnylam Pharmaceuticals during the 4th quarter worth $306,000. Institutional investors own 92.97% of the company’s stock.

Key Alnylam Pharmaceuticals News

Here are the key news stories impacting Alnylam Pharmaceuticals this week:

• Positive Sentiment: HC Wainwright reaffirmed a Buy rating and set a $510 price target, signaling sizable upside vs. the current share price. Article Title
• Positive Sentiment: Needham’s Joseph Stringer maintained a Buy rating and a $510 target, citing underpenetrated TTR market opportunity and commercial momentum. Article Title
• Positive Sentiment: Bank of America reiterated a Buy stance, highlighting durable ATTR growth and Amvuttra commercial momentum as upside drivers. Article Title
• Positive Sentiment: Chardan Capital reaffirmed a Buy rating with a $425 price target, reinforcing upside expectations from sell‑side analysts. Article Title
• Positive Sentiment: Alnylam announced a strategic collaboration with Viz.ai and support for the American Heart Association to advance earlier identification and care coordination for ATTR‑CM — a potential tailwind for market penetration and patient flow into Alnylam’s TTR treatments. Article Title
• Neutral Sentiment: A recent company transcript reviews strategy and progress in transforming ATTR care (useful for qualitative context but no new financials). Article Title
• Neutral Sentiment: Multiple news items report a rise in short‑interest figures but the publicly posted values show zeros/NaN and appear inconsistent — the data currently looks unreliable and likely isn’t driving the move. (Various short‑interest reporting entries)
• Negative Sentiment: On Feb. 12 Alnylam missed the quarter’s EPS estimate ($1.25 vs. $1.43) and posted revenue below consensus ($1.10B vs. $1.16B), a reminder that execution and near‑term results can still disappoint despite bullish sentiment; this remains a downside risk if future quarters miss expectations.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.